Treatment of Endometriosis and Leiomyoma with the Association of Miodesin and Gestrinone in Pentravan Through the Vaginal Route

Abstract

Hugo Maia, Wilson Saback, Clarice Haddad and Paulo R Sitya

Introduction: The effects of Myodesin™ (Fagron, Brazil) on uterine volume and pain scores were investigated in a group of patients with leiomyoma and endometriosis. Myodesin™ was used either alone or in combination with vaginal gastronone.

Patient and Methods: Forty two patients with uterine leiomyoma and endometriosis were enrolled for this study and divided into 3 groups according to the treatment scheme. In Group A (n=16) they were treated with a higher dose of vaginal Gastronome alone (5mg twice a week). In Group B (n=16) patients received a lower dose of Gestrinone (2.5 mg twice a week) together with vaginal Miodesin™ (500 mg/dose daily) (Fagron Brazil). In Group C (n=10) patients were treated only with Miodesin™. All medications were dispensed vaginally dissolved in Pentravan™ (Fagron, Netherland).

Results: The average uterine sizes before treatment were 200 cm3, 334 cm3, 242cm3 in group A, B and C respectively and they were not statistically different. After the second month a significant reduction in uterine volume was observed in all treated groups. However the reduction in uterine volume was greater in group than in group C. The proliferation rates in both stroma and endometrial gland measured by Ki-67 were low with a mean value of 2% with no significant differences between groups A and B. Treatment with Gestrinone decreased significantly total pain scores (VAS) when used either alone or in combination with Myodesin™. However this decrease was significantly greater in Group B than in Group A.Treatment with Miodesin alone (Group C) also decreased significantly pain scores.

Conclusion: Miodesin treatment increased the efficacy of Gestrinone to reduce pelvic pain and uterine volume in patients with endometriosis and leiomyoma.

PDF